Content about Alcohols

May 17, 2013
FDA advisory committee to meet in July on opioid painkiller

A Food and Drug Administration panel will consider whether to recommend approval for an experimental painkiller in July, the drug's developer said Friday.

May 13, 2013
FDA ruling on opioid painkiller deals blow to Endo

A ruling by the Food and Drug Administration means that generic versions of an opioid painkiller made by Endo Pharmaceuticals can stay on the market, drawing criticism from the drug maker.

May 9, 2013
OxyContin patent expires, fears of abuse return

The November 2011 expiration of Pfizer's patent on the cholesterol drug Lipitor and Ranbaxy Labs' release of the generic version received significant play in the media, particularly due to the theretofore status of Lipitor (atorvastatin calcium) as the drug with the highest sales in the country, $7.7 billion in the United States, according to healthcare analytics firm IMS Health.

May 1, 2013
Teva introduces generic bronchospasm drug

Teva Pharmaceutical Industries has launched a generic inhaler used to treat bronchospasm, the company said.

April 26, 2013
Actavis can launch generic OxyContin in January 2014 under settlement with Purdue

Generic drug maker Actavis is settling a patent-infringement suit with Purdue Pharma concerning the opioid painkiller OxyContin, Actavis said, saying it expected to make more than $100 million in the deal between 2014 and 2015.

April 24, 2013
FDA approves drug for opioid-induced constipation

The Food and Drug Administration has approved a new drug for constipation related to use of opioid painkillers made by Sucampo Pharmaceuticals and Takeda Pharmaceuticals, the drug makers said.

April 16, 2013
Authorities worry about abuse potential as OxyContin patent expires

Purdue Pharma's patent for OxyContin expired Tuesday, opening up the opioid painkiller to generic competition, but authorities have raised concerns about what they call the potential for generic versions to be abused.

April 16, 2013
FDA approves new labeling for OxyContin

The Food and Drug Administration will not approve generic versions of Purdue Pharma's painkiller OxyContin based on earlier versions of the drug that did not include features to thwart abuse, the agency said.

April 8, 2013
Teva introduces generic painkiller

Teva Pharmaceutical Industries has launched a generic opioid medication for treating pain, the company said.

April 4, 2013
Allergy Relief 2013

The March/April 2013 Allergy Relief Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Claritin-D, Allegra-D, Zyrtec-D, Benadryl-D, Advil Allergy and Congestion Relief, UrgentRx Allergy Attack, Hyland's Seasonal Allergy Relief, Similasan's Nasal Allergy Relief and Boiron's Sabadil.

March 26, 2013
FDA approves Actavis drug for opioid dependence

The Food and Drug Administration has approved a drug for opioid dependence made by Actavis, the company said.

March 18, 2013
FDA approves Mylan bronchospasm drug

The Food and Drug Administration has approved a generic treatment for bronchospasm made by Mylan, the drug maker said Monday.

March 14, 2013
FDA to review experimental opioid drug

The Food and Drug Administration will decide in late August whether to approve an experimental opioid painkiller made by QRxPharma, the drug maker said Thursday.

March 12, 2013
State, territorial attorneys general call for anti-tampering measures in opioids

The attorneys general of 46 states and two territories are calling on the Food and Drug Administration to make prescription painkillers harder to abuse.

March 5, 2013
Amneal ships opioid-dependence drug

Amneal Pharmaceuticals has started shipping a drug used to treat opioid dependence, the company said Tuesday.

March 5, 2013
Ranbaxy to market antidepressant drug

Ranbaxy Labs will market a drug for depression under an agreement with another company, the drug maker said Tuesday.

February 25, 2013
FDA approves Amneal opioid-dependence drug

Amneal Pharmaceuticals has received approval from the Food and Drug Administration for a drug to treat opioid dependence.

January 25, 2013
Merck: FDA approves Oxytrol for Women, creating overactive bladder category in OTC

Merck on Friday announced the Food and Drug Administration has approved the switch of Oxytrol for Women (oxybutynin transdermal system, 3.9 mg/day) from prescription-only to nonprescription, creating a new category — overactive bladder in women — in the OTC area.

January 9, 2013
WEB FEATURE: FDA guidance aims to encourage abuse-deterrent painkillers

One of the most serious drug abuse problems in the country doesn't involve heroin, methamphetamine or crack, but abuse of legal prescription drugs, particularly opioid painkillers, a problem that the Food and Drug Administration aims to change with draft guidance released Wednesday.

January 4, 2013
March of Dimes highlights folic acid for pregnant women

The March of Dimes is launching a campaign to encourage expectant mothers to take folic acid to prevent birth defects, the group said Friday.

January 3, 2013
Teva announces inhaler with dose counter for bronchospasm

An inhaler for patients with bronchospasm that includes a dose counter has become available from Teva Respiratory, the company said Thursday.

December 21, 2012
Federal court rules against Endo in painkiller case

A federal court decision means that a nontamper-resistant formulation of a painkiller made by Endo Health Solutions can enter the market early next month, the drug maker said.

November 20, 2012
Reports: Canada to allow generic OxyContin approval over provincial, tribal objections

Canadian regulators have allowed the approval process for a generic opioid painkiller to go forward despite objections from provincial and other authorities, according to published reports.

November 13, 2012
Study finds fourfold increase in OxyContin prescriptions dispensed near U.S.-Canada border tunnel

The launch of a tamper-resistant formulation of a popular opioid painkiller in the United States, but not in Canada, may have influenced a spike in dispensing rate of the original at pharmacies in Canadian border cities, according to a study.

October 29, 2012
Par acquires rights to generic version of Seroquel XR

Par Pharmaceutical Cos. has bought rights to a generic version of a drug used to treat bipolar disorder and schizophrenia.

© 2013 Drug Store News. All Rights Reserved.